Our R&D groups in oncology focus on a balanced portfolio of innovative targets, as well as more established approaches. These groups are organized around five Innovation Clusters:
- Oncogenic signaling
- Receptor Tyrosine Kinases (RTKs) and Antibody-Drug Conjugates
- Tumor Metabolism & Autophagy
- Wnt & Development Pathways
- DNA Damage & Repair
What do we seek from our partners in Oncology?
We actively search and evaluate technologies, preclinical and clinical assets that are able to support and strengthen our Innovation Clusters, and have clear differentiation potential.
Assets - Our search space includes antibodies against tumor antigens suitable for antibody-drug conjugation or pro-drug approaches for antibody therapeutics, as well as differentiated bi-specific platform technologies and antibody/protein scaffolds. Selective small molecule assets with well-defined molecular targets that show anti-tumor activity in specific contexts are also a priority, such as those with a proven synthetic lethality relationship in the area of DNA damage and repair, or those controlling tumorigenic metabolic networks in particular cancer genotypes.
Technologies - We seek methods such as those that allow the determination of drug sensitivity, detection of disease-relevant mutations in circulating DNA or tumor cells, or the identification of novel pharmacodynamic and stratification biomarkers. Such approaches might be in silico-based, or in an in vitro or in vivo setting, examples being high throughput sub-cellular analysis of drug localization/binding or innovative mouse models reflecting metabolic dependencies.